Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AUTL
SellHot AirAutolus Therapeutics plc · Healthcare · United Kingdom · $623M · Avg Vol: $6M/d
COMPANY DESCRIPTION
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development of programmed T-cell therapies for the treatment of cancer. The company advances a proprietary pipeline of next-generation CAR T-cell therapies, designed to overcome limitations of current treatments through sophisticated cell engineering. It is a specialized biotechnology firm at the forefront of cellular immunotherapy, aiming to deliver innovative and highly effective treatments for hematological and solid tumors.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5M | 6.2M | 1.7M | 10.1M | 75.4M | 165.9% | 1.1M | 149.8M | 192.4M | 59.8% |
| EPS | -1.97 | -1.57 | -1.20 | -0.86 | -1.08 | — | -1.06 | -0.79 | -0.63 | — |
| Shares | 90.9M | 173.1M | 174.1M | 266.1M | 266.1M | +192.8% | 266.2M | — | — | — |
| Debt | 21.0M | 24.3M | 53.0M | 52.6M | 71.4M | 35.8% | — | — | — | — |
| Equity | 313.3M | 298.7M | 111.5M | 427.3M | 178.1M | -13.2% | — | — | — | — |
| Op CF | -117.9M | -112.3M | -145.6M | -206.3M | -283.6M | — | -283.6M | — | — | — |
| Inv CF | -8.9M | -10.8M | -11.0M | -394.6M | 158.5M | — | — | — | — | — |
| Fin CF | 284.1M | 223.6M | -0.9M | 589.6M | -4.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AUTL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AUTL | Autolus Therapeutics plc(you) | $623M | 30 | Sell |
| SLN | Silence Therapeutics plc | $834M | 24 | Sell |
| OXB.L | Oxford Biomedica plc | $859M | 14 | Strong Sell |
| AVCT.L | Avacta Group Plc | $433M | 10 | Strong Sell |
| ONT.L | Oxford Nanopore Technologies plc | $2.3B | 32 | Sell |
| BCYC | Bicycle Therapeutics plc | $294M | 10 | Strong Sell |
| IMCR | Immunocore Holdings plc | $1.9B | 17 | Strong Sell |
| POLB.L | Poolbeg Pharma PLC | $89M | 25 | Sell |
| 4BB.L | 4basebio PLC | $110M | 10 | Strong Sell |
| GNS.L | Genus plc | $2.1B | 61 | Hold |
Peer medians: ROE -1.8% · P/E 24.4x · Gross margin 56.0%